(Q67674939)

English

A Dose Titration Study Evaluating Terazosin, a Selective, Once-a-Day α 1-Blocker for the Treatment of Symptomatic Benign Prostatic Hyperplasia

scientific article published on 01 December 1990

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

A Dose Titration Study Evaluating Terazosin, a Selective, Once-a-Day α 1-Blocker for the Treatment of Symptomatic Benign Prostatic Hyperplasia (English)

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

author name string

H. Lepor

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700152

2 November 2022

G. Knapp-Maloney

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700152

2 November 2022

H. Sunshine

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1700152

2 November 2022

language of work or name

0 references

publication date

1 December 1990

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

full work available at URL

https://api.elsevier.com/content/article/PII:S0022534717397513?httpAccept=text/xml

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

https://api.elsevier.com/content/article/PII:S0022534717397513?httpAccept=text/plain

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

http://www.jurology.com/doi/pdf/10.1016/S0022-5347%2817%2939751-3

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

144

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1393-7; discussion 1397-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Alpha-adrenergic blockers in prostatism

2

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

3

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation

4

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Bladder Outflow Obstruction Treated with Phenoxybenzamine

5

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Ineffectiveness of phenoxybenzamine in treatment of benign prostatic hypertrophy A controlled study

6

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation

7

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Effects of Prazosin in Patients with Benign Prostatic Obstruction

8

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

A double-blind controlled trial of a new alpha-1 blocking drug in the treatment of bladder outflow obstruction.

11

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Prazosin in the Treatment of Prostatic Obstruction A Placebo-controlled Study

12

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Use of an alpha 1-blocker, YM-12617, in micturition difficulty

13

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia

15

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Indoramin--an effective new drug in the management of bladder outflow obstruction

16

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Phenoxybenzamine in prostatic hypertrophy. A double-blind study

18

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

21

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Urodynamic and histological correlates of benign prostatic hyperplasia

22

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism

23

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Transurethral incision of prostate compared with transurethral resection of prostate in 132 matching cases.

24

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Bladder neck incision or transurethral electroresection for the treatment of urinary obstruction caused by a small benign prostate? A randomized urodynamic study

26

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Long-term Follow-up of Unilateral Bladder Neck Incision

30

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters

31

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Response of the benign hypertrophied prostate to treatment with an LHRH analogue

32

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

33

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

The Treatment of Benign Prostatic Hypertrophy with Flutamide (SCH 13521): A Placebo-Controlled Study

34

1 reference

10.1016/S0022-5347(17)39751-3

https://api.crossref.org/works/10.1016/S0022-5347(17)39751-3

2 November 2022

Identifiers

10.1016/S0022-5347(17)39751-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1700152%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67674939&oldid=1762775636"